IN THE UNITED STATES PATENT AN	ND TRADEMARK	CEICE	PATENT APPLICATION	<u>ИС</u>
	Group Art Un		<u> </u>	7
Inventor(s): BOUCHARD et al.	Examiner:	C. Delacroi	ix-Muirheid C	ñ
Appln. No.: 08 786,937	Atty. Dkt.	P 235299	960018P	
Series Code ↑ Filed: January 22, 1997 Hon. Commissioner of Patents Washington, D.C. 20231 Serial No. ↑ O \ P E	Appln. Title:	LHRH-ANTAGO TREATMENT O DISORDERS	Client Ref 2 6 2001 F FURTILES	PEIVE
Sir: REPLY/AMENDMERT/LETTER	Date:	June 22, 2001	00	O

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim A. ⊠ NOT made B. □ Withdrawn C. □ made herewith D. □ made previously For B & C See Required Separate Paper (Pat-256)	Claims remaining after amendment	Highest number previously paid for		Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	21	**minus	21	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims	2	***minus	3	0	x \$80/\$40 =	+ \$0	102/202
4. If amendment enters <u>proper</u> multiple dependent claim(s) into this application for <u>first</u> time (leave <u>blank</u> if this is a <u>reissue</u> application)							104/204
5. Original due Date:	☑ NONE ⑤						
date to cover the date this response is filed for which the requisite fee is attached (3 mos) \$3 (Usable only for ≤ 2mo.OA 4 mos) \$1				\$110/\$55 = \$390/\$195 = \$890/\$445 = \$1390/\$695= \$1890/\$945=	+ \$0	V.	115/215 116/216 117/217 118/218 128/228
7. Enter any previous extension fee paid since above original due date and subtract					- \$0		1.5
8. Extension Fee Attached					+ \$0	when the	
9. If Terminal Disclaimer attached, add Rule 20(d) official fee					+ \$110/\$55	+ \$0	148/248
10. If IDS attached requires Official Fee under Rule 97 (c),					+ \$180 + \$180	+ \$0	126 126
11. After-Final Request Fee per rules 129(a) and 17(r)					+ \$710/355	+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b)					x \$710/355 ea	+ \$0	149/249
13. Request for Continued Examination (RCE)					+ \$710/355	+ \$0	1179/1279
14. Petition fee for					+ \$0		
15. TOTAL FEE ENCLOSED =					\$0		

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

(Our Order No. 11468 235299 CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be

filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP Intellectual Property Group

1100 New York Avenue, NW Ninth Floor

Washington, DC 20005-3918

Tel: (202) 861-3000 Atty/Sec: BET/LMR

Blair E. Taylor By Atty:

Our Deposit Account No. 03-3975)

Reg. No. 44,370

(202) 822-0944 (202) 861-3797

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

^{17. **}If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

^{18. ***}If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

In re PATENT APPLICATION of

BOUCHARD, et al.

Group Art Unit: 1654

Appln. No.: 08/786,937

Examiner: Delacroix-Muirhead

Filed: January 22, 1997

FOR: LHRH-ANTAGONISTS IN THE

TREATMENT OF FERTILITY DISORDERS

June 22, 2001

PRELIMINARY AMENDMENT

Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

Prior to examination of this RCE on the merits, kindly consider and enter the following preliminary amendment and attendant remarks.

IN THE CLAIMS:

Kindly enter the following amended claims:

15. (Four Times Amended) In a method of treating infertility disorders by administering an LH-RH Antagonist and administering an exogenous gonadotropin for inducing follicle growth, the improvement comprising administering the LH-RH Antagonist within a controlled ovarian stimulation program either in a single or dual dose regimen of 1 to 10 mg or in a multiple dosage regimen of 0.1 to 0.5 mg per day.